ICD-10-CM Code D07.39

Valid for Submission

D07.39 is a billable code used to specify a medical diagnosis of carcinoma in situ of other female genital organs. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code D07.39 might also be used to specify conditions or terms like carcinoma in situ of broad ligament, carcinoma in situ of fallopian tube, carcinoma in situ of ovary, carcinoma in situ of parametrium, carcinoma in situ of round ligament of uterus, carcinoma in situ of uterine adnexa, etc

The code D07.39 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.

The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: adnexa (uterine) ; broad ligament ; corpus ; corpus albicans ; fallopian tube (accessory) ; genital organ or tract female NEC specified site NEC ; ligament [See Also: Neoplasm, connective tissue] ; etc

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:

• Diagnoses for females only - Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, this code applies to FEMALES only .

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Carcinoma in situ of broad ligament
• Carcinoma in situ of fallopian tube
• Carcinoma in situ of ovary
• Carcinoma in situ of parametrium
• Carcinoma in situ of round ligament of uterus
• Carcinoma in situ of uterine adnexa
• Neoplasm of round ligament of uterus
• Tis

Diagnostic Related Groups

The ICD-10 code D07.39 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). applicable from 10/01/2020 through 09/30/2020.

• 736 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC
• 737 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC
• 738 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC
• 739 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC
• 740 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC
• 741 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC

Convert D07.39 to ICD-9

• 233.39 - Ca in situ fem gen NEC (Approximate Flag)

Code Classification

• Neoplasms (C00–D48)
  • In situ neoplasms (D00-D09)
    • Carcinoma in situ of other and unspecified genital organs (D07)

Code History

• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
  (First year ICD-10-CM implemented into the HIPAA code set)
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Tools

• Copy Code
• Copy Description
• View Related Codes
• Convert D07.39 to ICD-9